oratocheri Posted - 4 days ago

$ALKS Another interesting potential buy .. any insiders?

DonCorleone77 Posted - 09/23/24

$ALKS Alkermes to present clinical data from its Phase 1b study of ALKS 2680 Alkermes announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2, NT2, and idiopathic hypersomnia, IH, at the European Sleep Research Society's, ESRS, 27th Congress, Sleep Europe 2024, taking place Sept. 24-27, 2024 in Seville, Spain. ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor, OX2R, agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. In an oral presentation and corresponding poster presentation, the company will share data from the cohort of patients with NT2 from the phase 1b, proof-of-concept study evaluating single-dose, oral administration of ALKS 2680. Additionally, the company will present a poster with data from the cohort of patients with IH from the same study. As previously announced, ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo in both cohorts.

Stock_Titan Posted - 09/23/24

$ALKS Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 https://www.stocktitan.net/news/ALKS/alkermes-to-present-positive-clinical-data-from-phase-1b-study-of-0c3cbscbdhtq.html

harmongreg Posted - 09/22/24

Dragonfly Capital - 5 Trade Ideas for Monday: Alkermes, Citigroup, Caterpillar, Neogen and EchoStar https://dragonflycap.com/5-trade-ideas-for-monday-alkermes-citigroup-caterpillar-neogen-and-echostar/ $ALKS $C $CAT $NEOG $SATS

Stock_Titan Posted - 1 month ago

$ALKS Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program https://www.stocktitan.net/news/ALKS/alkermes-announces-launch-of-7th-annual-alkermes-pathways-research-mibq66iuvi2v.html

k_rma Posted - 1 month ago

$PSIL $MNMD $CMPS $ALKS Hopefully the catalyst the field of psychedelics needs. US gov’t grant for clinical trial on psychedelic treatment of PTSD, traumatic brain injury. submission deadline: 10/4/24

StockInvest_us Posted - 1 month ago

Signal alert: $ALKS - Overbought Trend Short (Overvalued) https://stockinvest.us/l/vU1KaZnmwP

insidemoney Posted - 08/27/24

$ALKS Alkermes 14-Day RSI: 60.3 % from 52-Week Low: +27.0% % from 52-Week High: -15.0% Open Interest: 4,681 % Change: +51% Put/Call Ratio: 1.12 % Change: -40.0%

insidemoney Posted - 08/23/24

Options Spikes (Aug 22) $ALKS Alkermes % Change -1.00% Trade Count 121 Total Notional 114.1 K 90 Day Average 18.6 K Calls 113.4 K Puts 675 $GNTX Gentex % Change -0.20% Trade Count 84 Total Notional 124.5 K 90 Day Average 20.6 K Calls 118.5 K Puts 6 K

Stock_Titan Posted - 08/22/24

$ALKS Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 https://www.stocktitan.net/news/ALKS/alkermes-announces-initiation-of-vibrance-2-phase-2-study-evaluating-bez7uilty6ld.html

RiskVsReward Posted - 08/20/24

$ALKS Look at this chart! 🏆

contangoz Posted - 08/20/24

BLOOMY upbeat on deal $alks

Shlobby Posted - 08/19/24

$ALKS if you get stopped out once cut and try again. Big candle today

kinderspiel Posted - 08/19/24

today $FULC announced the appointment of isabel kalofonos as CCO & heather faulds as chief regulatory affairs & quality assurance officer. together, they will be instrumental in advancing losmapimod towards a new drug application submission & preparing for commercial launch. ms. kalofonos joins fulcrum from $IMGN where she served as senior vice president & chief commercial officer. most recently, ms. faulds served as svp, regulatory affairs at $ALKS

Fullratio Posted - 08/18/24

Healthcare sector stocks with high YoY EPS growth in Q2 2024: $JNJ $ALKS $NVS

kinderspiel Posted - 08/15/24

Aug 15 highest volume of shares traded $EXAS 410.6 k $NTRA 242.7 k $BEAM 158.6 k $ALKS 120.7 k $BPMC 101.0 k

StockInvest_us Posted - 2 months ago

Signal alert: $ALKS - Overbought Trend Short (Overvalued) https://stockinvest.us/l/JYHI4J7oTn

NVDAMillionaire Posted - 07/31/24

$ALKS Alkermes (ALKS): A Diversified Biopharma Poised for Continued Growth http://beyondspx.com/2024/07/31/alkermes-alks-a-diversified-biopharma-poised-for-continued-growth/

Stocksrunner Posted - 07/28/24

$ALKS Alkermes is in the spotlight after its post-earnings bump, with analysts deeming the stock fairly valued. https://stocksrunner.com/symbol/ALKS

Aigner_Andreas Posted - 07/26/24

TD SELL $ALKS at 25.52, Supp 23.01 Resis 28.04 R22 HiLo 34% T1Y 31 buy 2.5 fwdPE 26.6 DIV N/A #Alkermes p #stocks #trading #finance #market

PenkeTrading Posted - 07/25/24

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Alkermes Plc. Is that bullish or bearish? $ALKS #ALKS #nasdaq #tradingsignals #technicalanalysis

Stocksrunner Posted - 07/24/24

Wednesday Watchlist: Top Searched Stocks Here are today’s most searched stocks on stocksrunner.com: $AGEN $PYPL $ALKS $PKG $BBSI Keep an eye on these symbols as trading heats up today!

Stocksrunner Posted - 07/24/24

$ALKS Alkermes beats top-line and bottom-line estimates, reaffirming its FY24 outlook. This biopharmaceutical company has a history of delivering, and our attention is now on its future pipeline developments. https://stocksrunner.com/symbol/ALKS

John_Wick1234 Posted - 07/24/24

$ALKS Nice Triple Bottom.

DonCorleone77 Posted - 07/24/24

$ALKS Alkermes reports Q2 non-GAAP EPS 70c, consensus 70c Reports Q2 revenue $399.1M, consensus $393.35M. "Our Q2 results reflect solid execution across our business, delivering double-digit, year-over-year growth for our proprietary commercial product portfolio and robust profitability. We enter the second half of the year in a strong financial position with clear operational priorities to drive the performance of our commercial portfolio and advance our neuroscience development pipeline, including the phase 2 program for ALKS 2680 in narcolepsy type 1 and type 2," said CEO Richard Pops. "As a profitable, smid-cap biotech growth company with multiple commercial products and a development pipeline with significant value potential, we are executing our plan to become a leader in the field of neuroscience."

epsguid Posted - 07/24/24

$ALKS reported earnings of $1.16, consensus was $0.64 via @eWhispers #epsbeat http://eps.sh/d/alks

Stock_Titan Posted - 07/24/24

$ALKS Alkermes plc Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/ALKS/alkermes-plc-reports-second-quarter-2024-financial-j3qnjc5gxd9v.html

oregonstonker Posted - 07/19/24

$ALKS Im in on this one... The year over year net profit trends speak for themselves. sorry just had to throw myself out in the sizzle

Stock_Titan Posted - 07/17/24

$ALKS Alkermes to Report Second Quarter Financial Results on July 24, 2024 https://www.stocktitan.net/news/ALKS/alkermes-to-report-second-quarter-financial-results-on-july-24-491ilxrr5lw9.html

DonCorleone77 Posted - 3 months ago

$NBIX $ALKS $INDV Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid After Indivior (INDV) reduced FY24 guidance due to the removal of automatic Medicaid coverage renewals for Sublocade, Jefferies caught up with both Neurocrine (NBIX) and Alkermes' (ALKS) management teams and notes that neither is seeing a Sublocade-like impact regarding Medicaid claims going into Q2. The firm maintains a Buy rating and $175 price target on Neurocrine shares and a Buy rating and $50 price target on Alkermes.